Posted by Michael Wonder on 05 Aug 2021
G1 Therapeutics granted new technology add-on payment for Cosela (trilaciclib) by CMS
4 August 2021 - G1 Therapeutics today announced that CMS has granted a new technology add-on payment for Cosela (trilaciclib dihydrochloride) when administered to Medicare beneficiaries in the hospital inpatient setting.
It will become effective for provider billing on 1 October 2021.
An new technology add-on payment provides additional payment to hospitals above the standard Medicare Severity Diagnosis-Related Group payment amount.
This grant follows the receipt of a C Code for pass through hospital outpatient system use (effective 1 July 2021) and a permanent J Code for all sites of care (effective 1 October 2021).
